Stock Performance: KALA BIO Inc. saw a significant increase of 37.87% in after-hours trading, reaching $0.88, following a regular session close at $0.64, despite a year-to-date decline of 91.72%.
Securities Purchase Agreement: The company entered a Securities Purchase Agreement to raise up to $6 million through a private placement, with the first closing raising $1.8 million from the sale of preferred shares.
Loan Settlement: KALA BIO reached a loan settlement with Oxford Finance LLC, involving a $2 million cash payment and the issuance of 1.62 million common stock shares, which will reduce the loan balance by $7 million.
New Leadership: David Lazar was appointed as the new CEO of KALA BIO, effective from the first closing of the securities agreement, having previously served as CEO of Novabay Pharmaceuticals Inc.
Wall Street analysts forecast KALA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALA is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast KALA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALA is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
Current: 0.609
Low
1.50
Averages
1.50
High
1.50
Current: 0.609
Low
1.50
Averages
1.50
High
1.50
Morgan Stanley
Overweight
maintain
$28 -> $30
Al Analysis
2026-01-08
Reason
Morgan Stanley
Price Target
$28 -> $30
Al Analysis
2026-01-08
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Cullinan Therapeutics to $30 from $28 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$26 -> $27
2026-01-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$26 -> $27
2026-01-08
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Cullinan Therapeutics to $27 from $26 and keeps a Buy rating on the shares after the company announced its 2026 milestones.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KALA
Unlock Now
Clear Street
Buy
maintain
$22 -> $33
2025-12-09
Reason
Clear Street
Price Target
$22 -> $33
2025-12-09
maintain
Buy
Reason
Clear Street raised the firm's price target on Cullinan Therapeutics to $33 from $22 and keeps a Buy rating on the shares after the company announced updated data from the Phase 1 study of CLN-049. CLN-049's clinical data appear superior to most CD3 bispecifics, which reinforces its "differentiated biology and therapeutic potential," the analyst tells investors in a research note. Clear Street introduced an acute myeloid leukemia market model for CLN-049 with a 2028 launch and project risk-adjusted peak sales of $500M in 2040.
Mizuho
Outperform
to
Neutral
downgrade
$30
2025-09-30
Reason
Mizuho
Price Target
$30
2025-09-30
downgrade
Outperform
to
Neutral
Reason
Mizuho downgraded Kala Bio to Neutral from Outperform with a price target of $1.50, down from $30. The firm cites yesterday's negative Phase 2 results for the company's lead asset KPI-012 for the downgrade. Mizuho is \"very disappointed\" by the data and has been unable to connect with management. The analyst removed KPI-012 Kala's model and downgraded the shares.
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
